Kt-939 Oximidol
| Negotiable | 1 Piece (MOQ) |
Min. Order:
1 Piece
Port:
Suzhou, China
Payment Terms:
L/C, T/T, D/P
Jiangsu, China
Find Similar Products
Product Description
Company Info
Product Description
Applications
KT-939 can be incorporated into various skincare formulations such as serums, lotions, and creams, providing excellent whitening and spot-reducing effects.
Its high efficiency, safety, and stability make it a top-tier ingredient for cosmetic products. Whether for daily skincare or professional treatments, KT-939 delivers excellent results.
Key Benefits of KT-939
1.Superior Efficiency: KT-939's inhibition of tyrosinase is 300 times stronger than SymWhite 377, 100 times stronger than 4-butylresorcinol, and 4 times stronger than Thiamidol, making it the definite market leader.
2.Safe and Gentle: A 28-day, 32-subject trial showed KT-939 was non-irritating, with zero allergic reactions. Its antioxidant and anti-inflammatory benefits ensure safe, long-term use.
3.Effective at Low Concentrations: KT-939 shows impressive results at concentrations as low as 0.1%-0.5%. This flexibility allows easy integration into both luxury and mass-market products.
Product Details
Product Name: KT-939, OXIMIDOL
INCI: Methyloxetanecarbamido Thiazolyl Resorcinol
Purity: ≥99%
Appearance: Off-white powder
Recommended Dosage: 0.1%-0.5%
CAS:3081328-14-2
Address:
No. 20, Songbei Road, Suzhou Industrial Park, Suzhou, Jiangsu, China
Business Type:
Manufacturer/Factory
Business Range:
Chemicals, Health & Medicine
Main Products:
Materials, Kx-826 Koshine 826, Kt-939 Oximidol
Company Introduction:
Founded in 2009, Kintor Pharma focuses on developing innovative small molecules and biologic drugs for dermatology and oncology with substantial unmet needs, especially androgen receptor-related diseases.
On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939. HK.
The company has a diversified pipeline of small molecule innovative drugs and biological innovative drugs, including 6 products under clinical research and a number of projects under preclinical research. Kintor Pharma has been granted more than 110 patents worldwide.
Many of the company′s projects were listed as National Special Projects for Significant Novel Drugs Development during the 12th (2011-2015) and 13th (2016-2020) Five-Year Plans.
On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939. HK.
The company has a diversified pipeline of small molecule innovative drugs and biological innovative drugs, including 6 products under clinical research and a number of projects under preclinical research. Kintor Pharma has been granted more than 110 patents worldwide.
Many of the company′s projects were listed as National Special Projects for Significant Novel Drugs Development during the 12th (2011-2015) and 13th (2016-2020) Five-Year Plans.
Send your message to this supplier
